booster
Washington (AFP) - Barring the emergence of drastically different variants, Covid boosters will likely be recommended annually in a similar manner to influenza vaccines, US health officials said Tuesday. The announcement came after the Food and Drug Administration last week authorized updated bivalent shots against both the original strain of the coronavirus and the BA.4 and BA.5 lineages of the Omicron variant, which are predominant. "We likely are moving towards a path with a vaccination cadence similar to that of the annual influenza vaccine, with annual updated Covid-19 shots matched to th...
AFP
Washington (AFP) - A panel of US medical experts on Tuesday called for Omicron-specific boosters this fall, as anticipation mounts that Covid vaccines will be needed on an ongoing seasonal basis, as is the case for influenza. The committee, convened by the Food and Drug Administration (FDA), voted 19 in favor and two against the measure after a day spent reviewing available data, including projections about future waves and early results from vaccine makers. Senior FDA scientist Peter Marks summed up the complexity of the problem before the experts' meeting: making predictions about the future...
AFP
Washington (AFP) - Pfizer and BioNTech on Thursday announced positive results from a clinical trial on the safety and immune response of a third dose of their Covid vaccine in children aged five through 11, adding they would soon seek regulatory authorization. Third doses of the vaccine are recommended for those aged 12 and up, and a fourth dose was recently recommended for people over 50. Younger children -- except for those with immune compromising conditions -- have not been eligible for the third, making them more susceptible to infection from Omicron and its BA.2 subvariant. BA.2 is now ...
AFP
As parts of the world witness fresh outbreaks of Covid-19 infections, vaccination remains the most common pandemic management approach. Kruxd looks at the numbers behind the global disparity in the availability of COVID vaccinations. By Bhargavi Saikia Fifteen months since the first-ever shot of the COVID vaccine was administered, about 58 per cent of the world’s population is fully vaccinated. However, this number hides the disparity in the level of vaccination in different regions of the world. The great divide As the race to vaccinate people against COVID-19 continues, many countries have a...
Health Analytics
Washington (AFP) - The United States authorized the Pfizer and Moderna Covid vaccine boosters to all people aged 18 and older on Friday, as the world's hardest-hit country enters a new winter wave of the pandemic. Boosters were previously available to the immune compromised, over 65s, people at high risk of severe disease and people in high risk occupations. The new decision "helps to provide continued protection against Covid-19, including the serious consequences that can occur, such as hospitalization and death," said acting FDA commissioner Janet Woodcock in a statement. "This emergency us...
AFP
Washington (AFP) - The United States on Wednesday authorized the use of boosters of Pfizer's Covid-19 vaccine for people aged over 65, as well as adults at high risk of severe disease and those in high-exposure jobs. The announcement means a significant part of the population -- amounting to tens of millions of Americans -- are now eligible for a third shot six months after their second. "Today's action demonstrates that science and the currently available data continue to guide the FDA's decision-making for COVID-19 vaccines during this pandemic," said Janet Woodcock, acting head of the Food ...
AFP
Washington (AFP) - The Johnson & Johnson Covid vaccine is more effective when given as a two-dose regime, according to new data released by the company on Tuesday. A second shot given 56 days after the first provided 75 percent protection against symptomatic Covid in a global clinical trial, with that level rising to 94 percent in the United States. The reason behind this difference was not clear from the company's press release, but it could be linked to fewer variants in the US when the data accrued. It was 94 percent effective in preventing severe or critical Covid at least 14 days post fin...
AFP
Washington (AFP) - Moderna on Wednesday announced it had begun submitting an application to the US Food and Drug Administration to authorize a booster of its Covid vaccine after trial data showed a significant increase in antibodies against variants. The third shot of the vaccine, known as mRNA-1273, was given to 344 participants in a study six months after their second dose. The first two doses were 100 micrograms, while the booster was half that at 50 micrograms. An analysis showed the booster increased neutralizing antibody levels against variants of concern, including Delta by more than 4...
AFP
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら